DK0506821T3 - Hybridt protein C - Google Patents

Hybridt protein C

Info

Publication number
DK0506821T3
DK0506821T3 DK91901991.9T DK91901991T DK0506821T3 DK 0506821 T3 DK0506821 T3 DK 0506821T3 DK 91901991 T DK91901991 T DK 91901991T DK 0506821 T3 DK0506821 T3 DK 0506821T3
Authority
DK
Denmark
Prior art keywords
human
protein
modified
molecules
heavy chain
Prior art date
Application number
DK91901991.9T
Other languages
English (en)
Inventor
Donald C Foster
Richard D Holly
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK0506821T3 publication Critical patent/DK0506821T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK91901991.9T 1989-12-29 1990-12-28 Hybridt protein C DK0506821T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45885689A 1989-12-29 1989-12-29
US51537890A 1990-04-27 1990-04-27

Publications (1)

Publication Number Publication Date
DK0506821T3 true DK0506821T3 (da) 1998-03-30

Family

ID=27039137

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91901991.9T DK0506821T3 (da) 1989-12-29 1990-12-28 Hybridt protein C

Country Status (11)

Country Link
US (1) US5766921A (da)
EP (1) EP0506821B1 (da)
JP (1) JP3270462B2 (da)
AT (1) ATE163048T1 (da)
AU (1) AU7168591A (da)
CA (1) CA2071630C (da)
DE (1) DE69032029T2 (da)
DK (1) DK0506821T3 (da)
ES (1) ES2113878T3 (da)
GR (1) GR3026414T3 (da)
WO (1) WO1991009960A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
SV1999000067A (es) * 1998-06-01 2000-07-06 Lilly Co Eli Proteina humana c polipeptida ref. x-12279
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2002542832A (ja) * 1999-04-30 2002-12-17 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
CA2391651A1 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
AU2001232736A1 (en) * 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
AU1038802A (en) * 2000-10-18 2002-04-29 Maxygen Aps Protein c or activated protein c-like molecules
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1417055A4 (en) * 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
RU2396347C2 (ru) 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3688900T3 (de) * 1985-06-27 1998-06-10 Univ Washington Expression von Protein C.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0245949B1 (en) * 1986-04-09 1997-10-29 Eli Lilly And Company A method of using eukaryotic expression vectors comprising the bk virus enhancer
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
EP0296413A2 (en) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
JP2643968B2 (ja) * 1988-02-03 1997-08-25 サントリー株式会社 Ｋｅｘ２エンドプロテアーゼ及びその製造方法
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
FI85342C (fi) * 1989-02-03 1992-04-10 Tampella Oy Ab Foerfarande och anordning foer befuktning av partiklar i gasstroemningen.
WO1990010649A1 (en) * 1989-03-06 1990-09-20 The Board Of Regents Of The University Of Texas System Serpin resistant chymotrypsin superfamily proteases, particularly pai-1 resistant +-pa, complementary inhibitor mutants; compositions; genes; expression
WO1991002065A1 (en) * 1989-08-11 1991-02-21 Zymogenetics, Inc. Cell culture methods for producing activated protein c

Also Published As

Publication number Publication date
EP0506821A4 (en) 1992-11-04
EP0506821B1 (en) 1998-02-04
US5766921A (en) 1998-06-16
GR3026414T3 (en) 1998-06-30
DE69032029T2 (de) 1998-08-20
ES2113878T3 (es) 1998-05-16
DE69032029D1 (de) 1998-03-12
WO1991009960A1 (en) 1991-07-11
EP0506821A1 (en) 1992-10-07
AU7168591A (en) 1991-07-24
CA2071630A1 (en) 1991-06-30
CA2071630C (en) 2000-02-22
ATE163048T1 (de) 1998-02-15
JPH06502986A (ja) 1994-04-07
JP3270462B2 (ja) 2002-04-02

Similar Documents

Publication Publication Date Title
ES2113878T3 (es) Proteina c hibrida.
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
DE3484616D1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
DE69034261D1 (de) Antikörper gegen VLA-4
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE69133509D1 (de) Verfahren zur herstellung von beta-lactamen
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
HU895788D0 (en) Process for producing peptides and medical products containing them
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
ATE270327T1 (de) Verfahren zur präparation von humanem aktiviertem protein c
D'Amici et al. Recombinant clotting factor VIII concentrates: Heterogeneity and high‐purity evaluation
FI954889A7 (fi) Proteiini, jolla on TPO-aktiviteetti
DE69113049D1 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
UA23145A (uk) Спосіб визhачеhhя активhості бромелаїhу
Zbikowska et al. Vertebrate plasminogen
MX9504057A (es) Proteina que tiene actividad tpo.
DE60326157D1 (de) Verfahren zur identifizierung von modulatoren der glucoseaufnahme
NO20006091L (no) Humant protein C-polypeptid
BG60657B2 (bg) Човешки рекомбинантни интерлевкин-2 мутеини
ES2004438A6 (es) Un metodo para producir una proteina trombolitica